ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer
Open Access
- 4 June 2026
- journal article
- research article
- Published by MDPI AG in Journal of Molecular Pathology
- Vol. 7 (2) , 22
Abstract
Background/Objectives: Ataxia telangiectasia-mutated kinase is encoded by the ATM gene. This gene is altered in many cancer types; however, it is most relevant for eligibility of poly-ADP-ribose polymerase inhibitor (PARPi) therapy in metastatic castrate-resistant prostate cancer in Canada. Non-benign ATM alterations are relatively uncommon, seen in less than 10% of prostate cancers; however, many of these are variants of uncertain significance with limited evidence of clinical significance or actionability. Methods: To aid in variant classification of next-generation sequencing results, ATM immunohistochemistry (IHC) is performed on patient tumour samples to serve as patient-specific functional evidence for ATM protein loss. Results: ATM IHC demonstrates strong concordance with known loss-of-function variants and copy number losses. Additionally, it can be used to clarify ATM protein loss in cases involving variants of uncertain significance (VUSs) or copy number deletions. Conclusions: Incorporation of ATM IHC into clinical testing for prostate cancer represents a relatively cost-effective orthogonal approach that can rescue poor-quality NGS results and clarify the functional impact of ATM VUSs on protein expression. Overall, this strategy may provide useful supportive evidence in prostate cancer biomarker testing and interpretation.Keywords
This publication has 21 references indexed in Scilit:
- Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA MutationTargeted Oncology, 2025
- Variants of uncertain significance: At the crux of diagnostic odysseyGene, 2025
- Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directionsDiscover Oncology, 2025
- p53 immunohistochemistry staining is a rapid screening method for TP53 mutation in myeloid malignancies suitable for integration into routine diagnostic laboratory practicePathology, 2025
- Understanding variants of unknown significance and classification of genomic alterationsThe Oncologist, 2024
- Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound studyEuropean Journal of Cancer, 2022
- Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)Genetics in Medicine, 2022
- Olaparib for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2020
- ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerCancer Research, 2020
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013